Project leader Dr. Wang Feng

He is currently a researcher of Institute of Biophysics, Chinese Academy of Sciences, executive director of protein and peptide drug innovation platform of Institute of Biophysics, Chinese Academy of Sciences. In 2017, Chinese Academy of Sciences took the lead in the action of "100 Talents Program" academic talents (a) category. Before 2018, he had been engaged in biomedical research for a long time at calibr, the Scripps Research Institute and Novartis in the United States, Through more than ten years of research work, Dr. Wang Feng has accumulated a lot of experience in small molecule drug screening and innovative research in the field of biological macromolecular medicine, and has been engaged in cell, nature medicine, PNAs, Jem, JACS, angel W. Chemie Dr. Wang Feng first discovered and characterized a new antibody with super long variable region, which completely changed the traditional understanding of antibody structure, function and evolution. At the same time, this achievement was published in cell journal as a cover article. In particular, he has accumulated a lot of experience in immunotherapy including car-t. the research team led by him has developed a series of new drugs, which have been transferred to Pfizer and other large international pharmaceutical companies for further product development. He is also a member of the Executive Committee of the Gates Foundation's comprehensive platform for drug research and development in developing countries. He is also a project review expert of the French national scientific research agency and many disease foundations around the world, as well as a national major project review expert.